Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,349 matching trials from the live ClinicalTrials.gov search.

Filters: New Haven, Connecticut Clear all

Conditions: Intracerebral Hemorrhage
Interventions: Deferoxamine Mesylate, Placebo (for Deferoxamine Mesylate); Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 25
States / cities: Phoenix, Arizona • Palo Alto, California • San Francisco, California + 18 more

Conditions: Obesity
Interventions: Retatrutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 33
States / cities: Santa Ana, California • Aurora, Colorado • Hamden, Connecticut + 30 more

Conditions: Pelvic Pain Associated With Refractory Endometriosis
Interventions: BGS649, Placebo; Drug
Lead sponsor: Mereo BioPharma; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 42
States / cities: Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more

Conditions: Heart Failure, Type II; Diabetes
Interventions: Empagliflozin, Placebo Oral Capsule; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Interventions: Lepodisiran Sodium, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 17,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 222
States / cities: Birmingham, Alabama • Daphne, Alabama • Dothan, Alabama + 171 more

Conditions: Ovarian Carcinoma
Interventions: Sacituzumab govitecan; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Delirium
Interventions: Melatonin, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 65 Years and older
Enrollment: 277 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: PF-06480605, Placebo; Drug
Lead sponsor: Telavant, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: pegylated liposomal doxorubicin (PLD), VTX-2337, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 136
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Burbank, California + 104 more

Conditions: Driveline Heart-assisted Device Related Infection
Interventions: Not listed
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 15
States / cities: New Haven, Connecticut • Tampa, Florida • Atlanta, Georgia + 12 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Gan & Lee Insulin Glargine Injection, Lantus®; Biological
Lead sponsor: Gan and Lee Pharmaceuticals, USA; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 57
States / cities: Birmingham, Alabama • Tuscumbia, Alabama • Phoenix, Arizona + 45 more

Conditions: Healthy Participant
Interventions: PF-07220060; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Prostate Cancer Metastatic
Interventions: Opevesostat, Abiraterone acetate, Enzalutamide, Hydrocortisone, Fludrocortisone acetate, Prednisone, Dexamethasone; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 48
States / cities: Orange, California • Palo Alto, California • Riverside, California + 41 more

Conditions: Chest Pain, Dyspnea, Syncope, Hypotension
Interventions: Point-of-care ultrasound, Usual care; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Intracerebral Hemorrhage, Ischemic Stroke, Spironolactone
Interventions: Spironolactone Pill; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: New Haven, Connecticut • Winston-Salem, North Carolina • Philadelphia, Pennsylvania + 1 more

Conditions: Kidney Transplantation
Interventions: Cyclosporine, CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 37
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 14 more

Conditions: Overactive Bladder
Interventions: Vibegron; Drug
Lead sponsor: Urovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 64
States / cities: Homewood, Alabama • Phoenix, Arizona • Tempe, Arizona + 54 more

Conditions: Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Interventions: Tarlatamab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 18
States / cities: Los Angeles, California • Santa Monica, California • New Haven, Connecticut + 13 more

Conditions: Atherosclerosis
Interventions: Selnoflast, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 24
States / cities: Beverly Hills, California • Irvine, California • Los Angeles, California + 19 more

Conditions: Quality of Life, Implantable Cardiac Defibrillators, ICDs
Interventions: Quality of life; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 562 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: Denver, Colorado • New Haven, Connecticut • Rochester, Minnesota + 3 more

Conditions: Schizoaffective Disorder, Schizophrenia
Interventions: Haloperidol, Olanzapine; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Not listed
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 18
States / cities: Tuscaloosa, Alabama • Palo Alto, California • West Haven, Connecticut + 15 more

Conditions: Healthy
Interventions: tafamidis; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Peripheral Vascular Disease, Peripheral Arterial Disease
Interventions: Evero DCB, Paclitaxel DCB; Combination Product
Lead sponsor: Cook Research Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 12
States / cities: Long Beach, California • New Haven, Connecticut • Gainesville, Florida + 9 more

Conditions: Femoral Arterial Calcification, Peripheral Arterial Disease, Claudication, Critical Limb Ischemia
Interventions: Shockwave Intravascular Lithotripsy (IVL); Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: New Haven, Connecticut • Providence, Rhode Island

Search by objective public record fields.

Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis

Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Prevention of Delirium in Inpatients Utilizing Melatonin

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Driveline Silicone Skin Interface Registry

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research

A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Impact of Immediate Point-of-Care Ultrasound on Patients With Cardiopulmonary Symptoms in the Emergency Department

Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Stroke

Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

A Study of Symptoms and Quality of Life in Patients With Implantable Cardiac Defibrillators (ICDs) and Their Caregivers

To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia

A Study Comparing Amounts of Tafamidis (PF-06291826) in the Blood Without Food in Healthy Volunteers

EVERO Drug-coated Balloon (DCB) Randomized Trial

CRUSH PAD: Real-world Outcomes Following Use of Shockwave Intravascular Lithotripsy (IVL) Technology in Calcified Common Femoral Lesions